Camurus AB (0RD1.L) Stock Analysis & Winston Score

Camurus is a Swedish pharmaceutical company that develops and sells prescription medicines for serious, hard-to-treat conditions like opioid addiction, cancer pain, and hormone disorders. Its main product is Brixia (buprenorphine), a once-weekly or once-monthly injectable used to treat opioid use disorder, which is sold under the name Brixia in Europe and Brixsuko in other markets. The company's key technology is called FluidCrystal, a drug delivery platform that allows medicines to be released slowly inside the body over days or weeks. Camurus makes money by selling its injectable medicines to hospitals, clinics, and specialty pharmacies, primarily across Europe and the United States. With a gross margin above 90%, the business keeps most of what it earns from each sale, which reflects the high value of its patented drug delivery technology and limited direct competition in its niche. The main growth driver is expanding the use of its opioid addiction treatment in the U.S. market, though it faces the ongoing risk of patent challenges and competition from other long-acting addiction therapies.